Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09)

Prostate Cancer and Prostatic Diseases volume 18, pages 167–172 (2015)Cite this article

Subjects

Abstract

Background:

This study was initiated to explore the impact of organic cation transporter 1 (OCT1) and multidrug and toxin extrusion transporter 1 (MATE1) genetic polymorphisms on toxicity, and clinical activity of metformin in patients with castration-resistant prostate cancer (CRPC).

Methods:

The SAKK 08/09 trial included 44 patients with CRPC to receive single-agent metformin 1000 mg two times a day until disease progression or unwanted toxicity. Drug pathway-associated gene polymorphisms of OCT1 (rs622342) and MATE1 (rs2289669) were assessed. The primary objective of this study was to define the relationship between mutations in OCT1, MATE1 and progression-free survival (PFS) at 12 weeks absolute PFS and PSA response in consenting patients of SAKK 08/09. The secondary objective of this study was to analyze the association between mutations in OCT1, MATE1, metformin-related toxicity, PSA response at 12 weeks and overall survival.

Results:

Thirty-six patients were evaluable for pharmacogenetic analysis. Homozygous carriers of the polymorphic OCT1 C-allele had no metformin-related toxicity as compared with 41.9% for any metformin-related toxicity in carriers of at least one wild-type A-allele (P=0.07). Disease progression according to RECIST (Response Evaluation Criteria In Solid Tumors) was significantly more frequent in homozygous carriers of the polymorphic OCT1 C-allele (80%) as compared with carriers of at least one wild-type A-allele (28.6%) (P=0.002). Disease progression according to RECIST was also more frequent in carriers of at least one polymorphic MATE1 A-allele (44%) as compared with homozygous carriers of the wild-type G-allele (12.5%) (P=0.07). OCT1 and MATE1 were not associated with PFS.

Conclusions:

The polymorphic OCT1 C-allele has been shown to be associated with less metformin-related toxicity and a higher risk of tumor progression in patients with CRPC receiving metformin as an anticancer treatment. Polymorphisms in metformin drug transporters are attractive molecular markers to serve as potential predictors of efficacy in future clinical studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD . Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304–1305.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF et al. Metformin use and prostate cancer risk. Eur Urol 2014; 66: 1012–1020.

    Article  CAS  PubMed  Google Scholar 

  3. Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res 2011; 71: 4366–4372.

    Article  CAS  PubMed  Google Scholar 

  4. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 2010; 70: 2465–2475.

    Article  CAS  PubMed  Google Scholar 

  5. Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A et al. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis 2012; 15: 346–352.

    Article  CAS  PubMed  Google Scholar 

  6. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol 2013; 31: 3069–3075.

    Article  CAS  PubMed  Google Scholar 

  7. Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L . The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prev 2014; 23: 2111–2118.

    Article  CAS  PubMed  Google Scholar 

  8. Andrzejewski S, Gravel SP, Pollak M, St-Pierre J . Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2014; 2: 12.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bridges HR, Jones AJ, Pollak MN, Hirst J . Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 2014; 462: 475–487.

    Article  CAS  PubMed  Google Scholar 

  10. Pollak MN . Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012; 2: 778–790.

    Article  CAS  PubMed  Google Scholar 

  11. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014; 510: 542–546.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039–1047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Pollak M . Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 2014; 20: 591–593.

    Article  CAS  PubMed  Google Scholar 

  14. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y . Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Therap 2002; 302: 510–515.

    Article  CAS  Google Scholar 

  15. Kimura N, Okuda M, Inui K . Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005; 22: 255–259.

    Article  CAS  PubMed  Google Scholar 

  16. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M . Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005; 70: 1851–1860.

    Article  PubMed  Google Scholar 

  17. Koepsell H . Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci 2004; 25: 375–381.

    Article  CAS  PubMed  Google Scholar 

  18. Koepsell H, Lips K, Volk C . Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227–1251.

    Article  CAS  PubMed  Google Scholar 

  19. Meyer ZU, Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB . Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010; 298: F997–F1005.

    Article  Google Scholar 

  20. Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280.

    Article  CAS  PubMed  Google Scholar 

  21. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86: 299–306.

    Article  CAS  PubMed  Google Scholar 

  22. Christensen MM, Brasch-Andersen C, Green H, Nielsen F, Damkier P, Beck-Nielsen H et al. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet Genom 2011; 21: 837–850.

    Article  CAS  Google Scholar 

  23. Christensen MM, Pedersen RS, Stage TB, Brasch-Andersen C, Nielsen F, Damkier P et al. A gene–gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genom 2013; 23: 526–534.

    Article  CAS  Google Scholar 

  24. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Therap 2013; 93: 186–194.

    Article  CAS  Google Scholar 

  25. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422–1431.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009; 58: 745–749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenom J 2009; 9: 242–247.

    Article  CAS  Google Scholar 

  28. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH . Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genom 2010; 20: 38–44.

    Article  CAS  Google Scholar 

  29. Tarasova L, Kalnina I, Geldnere K, Bumbure A, Ritenberga R, Nikitina-Zake L et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genom 2012; 22: 659–666.

    Article  CAS  Google Scholar 

  30. Tkac I, Klimcakova L, Javorsky M, Fabianova M, Schroner Z, Hermanova H et al. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obes Metab 2013; 15: 189–191.

    Article  CAS  PubMed  Google Scholar 

  31. Toyama K, Yonezawa A, Masuda S, Osawa R, Hosokawa M, Fujimoto S et al. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Br J Pharmacol 2012; 166: 1183–1191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Rizos CV, Elisaf MS . Metformin and cancer. Eur J Pharmacol 2013; 705: 96–108.

    Article  CAS  PubMed  Google Scholar 

  33. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human u. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med 2001; 47: 45–50.

    Google Scholar 

  34. Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bartschi D et al. Metformin in chemotherapy-naive castration-resistant prostate cancer: A Multicenter Phase 2 Trial (SAKK 08/09). Eur Urol 2014; 66: 468–474.

    Article  CAS  PubMed  Google Scholar 

  35. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–1159.

    Article  PubMed  Google Scholar 

  36. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

    Article  CAS  PubMed  Google Scholar 

  37. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M . Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011; 30: 1174–1182.

    Article  CAS  PubMed  Google Scholar 

  38. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014; 508: 108–112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013; 23: 143–158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M et al. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 2014; 148: 81–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology and Hematology, Cantonal Hospital, St Gallen, Switzerland,

    M Joerger, S Gillessen & C Rothermundt

  2. Department of Clinical Chemistry, Erasmus University Medical Center Rotterdam/ Erasmus MC Cancer Institute, Rotterdam, The Netherlands

    R H N van Schaik

  3. Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands

    M L Becker

  4. Pharmacy Foundation of Haarlem Hospitals, Haarlem, The Netherlands

    M L Becker

  5. Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center, Bern, Switzerland

    S Hayoz

  6. Lady Davis Institute for Medical Research Jewish General Hospital and McGill University, Montréal, QC, Canada

    M Pollak

  7. Department of Medical Oncology, Cantonal Hospital, Chur, Switzerland

    R Cathomas

  8. Department of Medical Oncology, Cantonal Hospital, Lucerne, Switzerland

    R Winterhalder

Authors
  1. M Joerger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R H N van Schaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M L Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Hayoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Pollak
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Cathomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Winterhalder
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S Gillessen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Rothermundt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Joerger.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Joerger, M., van Schaik, R., Becker, M. et al. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 18, 167–172 (2015). https://doi.org/10.1038/pcan.2015.8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2015.8

This article is cited by

Search

Advanced search

Quick links